Navigation Links
Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven
Date:4/3/2009

studies within the framework of intensified insulin therapy. One study investigated various treatment schemes. This study on insulin glargine lasted 5 years; all the other studies lasted a maximum of 12 months.

It is notable that in 7 of the 9 studies comparing insulin glargine and human insulin, the drugs were not used as normally used in Germany. The study participants only injected the drugs once daily, even though in daily practice they are often injected more frequently. The relevance of these studies is therefore limited.

Conclusions about late complications of diabetes are hardly possible

It is not possible to draw reliable conclusions about the long-term advantages and disadvantages of the drugs investigated, solely due to the short duration of most studies. Even the 5-year study on insulin glargine, the results of which were not available at the time of the preparation of the preliminary report, only allows limited conclusions about late complications of diabetes. Regarding heart disease, the comparison with NPH insulin does not provide indications of a difference between treatment options. Similarly, the data do not provide indications that insulin glargine is associated with a higher risk of damage to the ocular fundus. This suspicion had prompted the US regulatory authority FDA (Food and Drug Administration) to request a long-term study from the manufacturer (Sanofi-Aventis). This study has now been completed and is assessed in the IQWiG report.

Data provide an indication of less frequent severe hypoglycaemia in patients using insulin glargine

The data do not prove short-term advantages of LAIAs, either. However, the data do provide some indications: in certain treatment schemes, non-severe hypoglycaemia seems to occur less frequently with insulin detemir, in consideration of the individual lowering of HbA1c levels. However, this only applies to the use as basal insulin (once or twice daily) i
'/>"/>

Contact: Dr. Anna-Sabine Ernst
info@iqwig.de
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. US Back Pain Market Approaches $23 Billion in 2018 - Anticipated Long-Acting, Abuse-Resistant Opioids Drive Value
2. Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R)
3. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
4. Studies Ignite Hope for Long-Acting Allergy Vaccines
5. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
6. Plain-Language Guides Detail Insulin Treatments
7. OmniPod(R) Insulin Management System Wins 2009 Edison Best New Product Award
8. NICE SUGAR: Intensive insulin therapy risks
9. Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan
10. Gene Explains How High-Fructose Diets Lead to Insulin Resistance
11. Ethnicity May Drive Response to Obesity, Insulin Resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... (PRWEB) April 18, 2015 Patients who ... of developing mesothelioma later in life, but the disease ... mesothelioma that is unrelated to radiation. Surviving Mesothelioma has ... its website. Click here to read it now. ... compared the cases of 45 patients who had both ...
(Date:4/18/2015)... April 18, 2015 In the past ... couple of changes. , "We had to run maintenance ... needed changes," said Jennifer Ramirez, the PR Director. "It ... to say that we are back on track after ... the process of changing phone systems which has not ...
(Date:4/18/2015)... On April 14th, 2015, Symantec released ... they say, “exposes a tactical shift by cyberattackers.” With everything ... introduced in 2014 - almost a million a day - ... be identified and patched by prominent manufacturers – as long ... business in a digital world can be fraught with peril, ...
(Date:4/18/2015)... ArcAngel ” was featured on NewsWatch as part of its ... coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers how ... turbulent world, people may find themselves in dangerous situations where ... move, but some situations can be avoided if there was ...
(Date:4/18/2015)... Canada (PRWEB) April 18, 2015 French ... emotions on food choices when he uttered, “Tell me ... you are.” Using food to cope with stress or ... by Queendom.com indicates otherwise. Data collected from ... genders fall victim to emotional eating, but for different ...
Breaking Medicine News(10 mins):Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... ELMWOOD PARK, N.J., July 2 PhytoCeuticals, Inc., ... care,formulations, who is the Fast to invent Stable ... granting IS Clinical from,Innovative Skin Care the right ... Inc. effective July 1, 2008., The IS ...
... and Eliza Hall Institute (WEHI) has contributed significantly ... biotechnology company, Bionomics, (ASX:BNO) and Germany-based pharmaceutical company, ... Licensing Agreement, Merck Serono will seek to develop ... autoimmune conditions. These prospective treatments will be based ...
... July 2 SuperGen, Inc.,(Nasdaq: SUPG ), ... and commercialization of therapies for solid tumors and,hematological ... and Chief Executive Officer, is scheduled to present ... 9, 2008 at the,Mandarin Oriental Hotel in New ...
... 2 The Female Health Company,(Amex: FHC ) ... Russell,Microcap(R) Index after the Russell Investment Group reconstituted its,comprehensive ... 27, 2008., The Russell Microcap(R) Index measures the ... the U.S. equity market. The Russell,Microcap(R) Index includes the ...
... Calif. and YOKOHAMA CITY, Japan, July 2 ... technology company,and Tokyo Electron Device Limited (TED), ... of inrevium evaluation board solutions, and,provider of ... the,distribution of Samplify,s patented Prism(TM) signal compression ...
... improved version of AmWay's MagnaBloc. , ... Memphis, TN ... pain management, is now available in a new, stronger form: ... released in the United States, and will be available worldwide within ...
Cached Medicine News:Health News:Termination of IS Clinical From Distributing PhytoCeuticals Formulas 2Health News:MS drug development agreement based on WEHI's medicinal chemistry 2Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2Health News:The Female Health Company Added to Russell Microcap(R) Index 2Health News:The Female Health Company Added to Russell Microcap(R) Index 3Health News:The Female Health Company Added to Russell Microcap(R) Index 4Health News:Samplify Systems Announces Distribution Agreement With Tokyo Electron Device Limited, Broadening Availability of Signal Compression Technology 2Health News:New MagnaBloc™ Product Available from Gradient Medical 2
(Date:4/17/2015)... -- ASSESS shows   plasma circulating tumour ... alternative to tumour biopsy   IGNITE supports ... NSCLC   AstraZeneca today presented results from two ... (ctDNA) testing for epidermal growth factor receptor (EGFR) mutation status ... (NSCLC) in clinical practice. [ 1 ] ...
(Date:4/17/2015)... DETROIT , April 17, 2015  In ... poverty, the infant mortality rate is two and one half ... live births. Nearly 6 of 10 infants that die in ... care.  These are sobering statistics that Covenant Community Care, a ... Metro Detroit, is poised to change thanks to a charitable ...
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... the "Medical Oxygen Systems - Global Strategic Business ... report analyzes the worldwide markets for Medical Oxygen Systems ... Liquid Oxygen Systems, Oxygen Cylinders & Regulators, and Oxygen ... the US, Canada , ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2
... CoaguChek System has been providing accurate, reliable PT/INR ... point of care. , The CoaguChek System is ... self-testing when monitoring on Coumadin (warfarin sodium) therapy. ... a result from a fingerstick drop (10ul) of ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
... The ADC drugs of abuse tests are ... at the SAMHSA recommended cut-off as confirmed by ... result. A more specific alternative method (such as ... a confirmed result. Professional judgment should be applied ...
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: